The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

PET-CT scans combine structural and functional imaging to detect diseases early. This technology improves diagnosis accuracy ...

An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic castration-resistant prostate cancer (mCRPC), whereas prostate-specific membrane ...

Prostate cancer focal therapies include cryotherapy, irreversible electroporation ablation (IRE), & high-intensity focused ultrasound (HIFU).

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with (18)F-DCFPyL in Prostate Cancer Patients (OSPREY). The Journal of urology.

On Thursday this week, the Aga Khan University Hospital sent a statement announcing it had also conducted the treatment.This therapy uses a radioactive substance, Lutetium-177, to target and kill ...

The report provides a detailed analysis of the current marketed drugs and late-stage pipeline drugs.

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.

In recent years, there has been a headlong rush into the use of prostate-specific membrane antigen (PSMA)–targeted PET for the staging and restaging of men with prostate cancer (PC). To date, there ...

We read with great interest the published results of the RADIOSA trial by Giulia Marvaso and colleagues.1 This well designed ...